Compare Dyne Therapeutics Inc. Common Stock (DYN) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while YieldMax NVDA Option Income Strategy ETF trades at $11.98 (market cap $1.39B). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 2.1× YieldMax NVDA Option Income Strategy ETF's market cap, and Dyne Therapeutics Inc. Common Stock is more actively traded (3,341,579 versus 1,855,603). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and YieldMax NVDA Option Income Strategy ETF for 44 Days on average.
| DYN | NVDY | |
|---|---|---|
Market Cap | $2.86B | $1.39B |
Volume | 3,341,579 | 1,855,603 |
Sector | Health | Income / Options Overlay |
52-Week High | $26.78 | $17.21 |
52-Week Low | $14.60 | $11.58 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.54, up 0.88% on the day. The technical outlook is bearish, with moving averages signaling strong selling pressure, though oscillators are neutral. The fund generates weekly dividends but faces structural limitations on upside participation. Recent news highlights concerns over net asset value erosion despite high distribution yields.
The outlook is cautious; while NVDY offers high income, its strategy caps gains during NVIDIA rallies and may underperform in low-volatility environments. Key risks include NAV decay and reduced option income potential. Investors seeking pure NVIDIA exposure may find direct ownership more attractive for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
